Abstract

The treatment of patients with early stage breast cancer has changed in recent years due to the introduction of pembrolizumab, olaparib, and abemaciclib. These and other drugs with the same class of active ingredient are currently in trial for various indications. This review article summarizes the latest results that have either been presented at major conferences such as the ESMO 2022 or published recently in international journals. This includes reports on newly discovered breast cancer genes, atezolizumab in neoadjuvant therapy in HER2-positive patients, long-term data from the APHINITY study, and on how preoperative peritumoral application of local anesthetics can influence the prognosis. We also present solid data on dynamic Ki-67 from the ADAPT studies.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Volume83
Issue number03
Pages (from-to)289-298
Number of pages10
ISSN0016-5751
DOIs
Publication statusPublished - 03.2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)
  • Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

  • 2.22-14 Hematology, Oncology
  • 2.22-21 Gynaecology and Obstetrics

Fingerprint

Dive into the research topics of 'Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer'. Together they form a unique fingerprint.

Cite this